Register
Login:
Share:
Email Facebook Twitter


EXCLUSIVE: David Lenigas answers investor questions in a detailed interview about UKOG, Doriemus, LGC Capital, AfriAg and Angus Energy.


Scancell Holdings Share Chat (SCLP)



Share Price: 14.00Bid: 13.75Ask: 14.25Change: 0.00 (0.00%)No Movement on Scancell Hldgs
Spread: 0.50Spread as %: 3.64%Open: 14.25High: 14.25Low: 14.00Yesterday’s Close: 14.00


Share Discussion for Scancell Holdings


Thread View

Please login or register to post a message on Share Chat.

Posts per page:


ratcliffewriter
Posts: 7,402
Observation
Opinion:Strong Buy
Price:14.00
View Thread (4)
RE: Ratty.
Today 09:25
Bl00dy hell aggie! That's a textbook ramp if ever there was.
 
crumbs
Posts: 11,318
Off Topic
Opinion:No Opinion
Price:14.00
View Thread (2)
RE: Ratty.
Today 09:16
Comedy gold....
agema
Posts: 3,647
Off Topic
Opinion:No Opinion
Price:14.00
Ratty.
Today 09:01
I never ramp. Unlike most. I don£t ever feel the need to.

Links are old news. Links means the sp has already gone.

At times I get good vibes. They are very rarely wrong. Merl and pfc are very well priced. Very nice rises will come on them two for Definate. Now is the right time to buy them.

Going to the states for three weeks on Monday. While there going on a horror night. Guess I£ll see you there. Gotta go, a lot to do today.
ratcliffewriter
Posts: 7,402
Observation
Opinion:Strong Buy
Price:14.00
View Thread (2)
RE: Hi c7
Today 08:05
Have you got a link to back that up aggie? Or is it just another of your pathetic ramps?
agema
Posts: 3,647
Off Topic
Opinion:No Opinion
Price:14.00
Hi c7
Today 06:37
Go on son ramp it up. Lol. Not too obvious.

Opti will have a good week next week.
CHELSEA7
Posts: 28,635
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:14.00
View Thread (2)
3rd time lucky!!!
Today 06:28
CHELSEA7
Posts: 28,635
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:14.00
Try this link
Today 06:27
hTTp://freshthinking.cellohealth.com/post/102eiev/are-hot-tumours-better-for-you
CHELSEA7
Posts: 28,635
Premium Chat Member
Off Topic
Opinion:Buy
Price:14.00
View Thread (2)
Morning All
Today 06:12
Another really good post by goosed on ADVFN, and something which LD explained to us all at the AGM and was in the recording.........................

What was it Prof. Durrant said about Moditope, turning Cold tumours Hot . . . . ?

Anyway - seems others are beginning to catch up on her thinking

hTTp://freshthinking.cellohealth.com/post/102eiev/are-hot-tumours-better-for-you

Fills me with enormous confidence in her work and hoping all the further clinical development really is for the betterment of patients and all of us PIs.
CHELSEA7
Posts: 28,635
Premium Chat Member
Off Topic
Opinion:Buy
Price:14.00
View Thread (4)
Repost of FT Article
Sat 06:00
Please use the sharing tools found via the email icon at the top of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found at https://www.ft.com/tour.
https://www.ft.com/content/5e49e822-828c-11e7-a4ce-15b2513cb3ff

Scancell Holdings

Aim-listed Scancell, which has a market capitalisation of about £34m, has developed two technologies that have allowed it to create vaccines to treat cancers through harnessing the immune system to overcome a tumour£s defences against detection and destruction.

The first, called ImmunoBody, enables the company to generate DNA vaccines that stimulate anti-tumour T-cells. The first product to emerge from ImmunoBody is a vaccine for the treatment of melanoma. Richard Goodfellow, chief executive, says this has shown £outstanding survival data£, with eight of the patients treated in early stage clinical trials having reached the five-year survival mark.

Its second platform, Moditope, targets advanced or hard-to-treat cancers. Enrolment for the first human clinical studies for this are expected to begin next year.

Hardman & Co, a consultancy, says that with two differentiated platforms that could be applied to many types of cancer, £Scancell£s products will become part of the overall immunotherapy segment of the market, which is clearly a multibillion-dollar opportunity£.

On Friday the company£s share price was about 10p £ down from 18p a year ago.

Noting that at one point the company£s market cap had been about £100m, Mr Goodfellow says £growth and valuation of companies like ours is not a linear process£ as it tends to depend on the announcement of breakthroughs. When Scancell revealed the discovery of its most recent technology, Moditope, £everyone wanted to buy the shares, and in a thinly-traded market it went up from 5p to 60p in the space of a few months£.

And another chance to hear the AGM Recording thanks to steve67..............

SCLPAGM Recording ...10 Oct '17
Cleaned up, amplified, pop & click filtered, noise reduction filtered.... I'm surprised it sounds this good!

https://www.dropbox.com/s/4p921ouc7t18475/SCLP_2017_Enhanced.mp3?dl=0

A particularly interesting bit around Moditope / platform / disruptive at about 55 mins ...
CHELSEA7
Posts: 28,635
Premium Chat Member
Off Topic
Opinion:Buy
Price:14.00
View Thread (2)
Ratty
Fri 20:28
Interesting post, Roche was often discussed as a preferred Pharma to us, just wonder what our two platforms Immunobody and Moditope can mutually do for us both, an interesting piece..................

""And therein is one of the ironies of pharma investing £ investors talk about peak revenue targets that are a decade away, but they£ll buy and sell in the short term on the basis of a half-point of operating margin.""

Not much difference with the AIM market in Biotech stocks in a different way.

No great surprises today, I trust the few trades over 14p were buys. Began the week 14/14.50, ended it 13.75/14.25. A pretty decent consolidation after that 15%"" AGM"""rise. Always a good time to get some news, JC did mention we couldn"t put off AGM for news to come, with that in mind next week would be one of those ""good times"".

Have a good weekend all.




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.